Patents by Inventor Pravin Iyer

Pravin Iyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230227483
    Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.
    Type: Application
    Filed: July 6, 2022
    Publication date: July 20, 2023
    Inventors: Pravin IYER, Sanjib DAS, Murugan CHINNAPATTU, Sachin CHAUDHARI, Jagmohan SAINI, Sravan MANDADI, Nagaraj GOWDA, Dnyaneshwar DAHALE, Sandip PATIL, Nanasaheb KADLAG, Chandrasekhar MISRA, Priyanka PANGARE
  • Publication number: 20230009626
    Abstract: The present disclosure is directed to compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein ring A, ring C, X1, X2, L1, R1, R2, R3, R4, R5, R6, R7, m and n are as defined herein, which are useful as MAP4K1 inhibitors, processes for their preparation, pharmaceutical compositions comprising the compounds, and the use of the compounds or the compositions in the treatment or prevention of various diseases, conditions and/or disorders mediated by MAP4K1.
    Type: Application
    Filed: October 7, 2019
    Publication date: January 12, 2023
    Inventors: Sachin Sundarlal CHAUDHARI, Laxmikant Atmaram GHARAT, Pravin IYER, Sachin Vasantrao DHONE, Bharat Gangadhar ADIK, Prashant Dilip WADEKAR, Nagaraj GOWDA, Malini BAJPAI
  • Publication number: 20220281815
    Abstract: The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.
    Type: Application
    Filed: April 29, 2022
    Publication date: September 8, 2022
    Inventors: Sridharan RAJAGOPAL, Mahanandeesha S. HALLUR, Purushottam DEWANG, Kannan MURUGAN, Durga Prasanna KUMAR C.H., Pravin IYER, Chandrika MULAKALA, Dhanalakshmi SIVANANDHAN, Sreekala NAIR, Mohd ZAINUDDIN, Subramanyam Janardhan TANTRY, Chandru GAJENDRAN, Sriram RAJAGOPAL
  • Patent number: 11352322
    Abstract: The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: June 7, 2022
    Assignee: Jubilant Epicore LLC
    Inventors: Sridharan Rajagopal, Mahanandeesha S. Hallur, Purushottam Dewang, Kannan Murugan, Durga Prasanna Kumar C. H., Pravin Iyer, Chandrika Mulakala, Dhanalakshmi Sivanandhan, Sreekala Nair, Mohd Zainuddin, Subramanyam Janardhan Tantry, Chandru Gajendran, Sriram Rajagopal
  • Patent number: 11236045
    Abstract: The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1? activity and interleukin-18 (IL-18) is implicated.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: February 1, 2022
    Assignee: Cadila Healthcare Limited
    Inventors: Rajiv Sharma, Pravin Iyer, Sameer Agarwal
  • Publication number: 20210052597
    Abstract: Present invention relates to compounds of formula (1) its enantiomers, diastereomers, racemic mixtures and their pharmaceutically acceptable salts. This invention also directed to antibacterial drug compounds that are capable of treating bacterial infection which are hard to treat with existing drug compounds.
    Type: Application
    Filed: January 28, 2019
    Publication date: February 25, 2021
    Inventors: Rajiv SHARMA, Pravin IYER, Jigar DESAI, Sanjay S. KUMAR
  • Publication number: 20200308110
    Abstract: The present disclosure describes novel compounds of the general Formula (I), their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds can inhibit both LSD and HDAC and are useful as therpeautic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, parkinson's disease and the like.
    Type: Application
    Filed: May 8, 2017
    Publication date: October 1, 2020
    Inventors: Sridharan RAJAGOPAL, Mahanandeesha S. HALLUR, Purushottam DEWANG, Kannan MURUGAN, Durga Prasanna KUMAR C.H., Pravin IYER, Chandrika MULAKALA, Dhanalakshmi SIVANANDHAN, Sreekala NAIR, Mohd ZAINUDDIN, Subramanyam Janardhan TANTRY, Chandru GAJENDRAN, Sriram RAJAGOPAL
  • Publication number: 20200140382
    Abstract: The present invention relates to novel heterocyclic compounds of the general formula (I) their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, diastereomers and polymorphs. The invention also relates to processes for the preparation of the compounds of invention, pharmaceutical compositions containing the compounds and their use as the compounds of the invention belong to the family of NOD-like receptor family (NLR) protein NLRP3 modulators. The present invention thus relates to novel NLRP3 modulators as well as to the use of the novel inhibitor compounds in the treatment of diseases or conditions as well as treatment of disease states mediated by NLRP3 as well as treatment of diseases or conditions in which interleukin 1? activity and interleukin-18 (IL-18) is implicated.
    Type: Application
    Filed: June 8, 2018
    Publication date: May 7, 2020
    Applicant: CADILA HEALTHCARE LIMITED
    Inventors: Rajiv SHARMA, Pravin IYER, Sameer AGARWAL
  • Patent number: 9957253
    Abstract: The present invention relates to triaminopyrimidines and to pharmaceutically acceptable salts thereof, to their use in the treatment and/or prevention of malaria caused by plasmodium species, and to their methods of preparation.
    Type: Grant
    Filed: March 26, 2015
    Date of Patent: May 1, 2018
    Assignee: MMV MEDICINES FOR MALARIA VENTURE
    Inventors: Shahul Hameed Peer Mohamed, Vikas Patil, Kannan Murugan, Eknath Vithalrao Bellale, Anandkumar Raichurkar, Sudhir Landge, Jayashree Puttur, Nilanjana Roy Choudhury, Gajanan Shanbhag, Krishna Koushik, Pravin Iyer, Vasan Kirthika Sambandamurthy, Suresh Solapure, Shridhar Narayanan
  • Patent number: 9725436
    Abstract: Embodiments of the present invention relate to novel cytochrome P450 inhibitors and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the production of cortisol that include metabolic syndrome, obesity, headache, depression, hypertension, diabetes mellitus, Cushing's Syndrome, pseudo-Cushing syndrome, cognitive impairment, dementia, heart failure, renal failure, psoriasis, glaucoma, cardiovascular disease, cancer, stroke or incidentalomas.
    Type: Grant
    Filed: September 15, 2014
    Date of Patent: August 8, 2017
    Assignee: CORTENDO AB (PUBL)
    Inventors: Benjamin Eric Blass, Magid A Abou-Gharbia, Wayne E. Childers, Pravin Iyer, Joshodeep Boruwa
  • Publication number: 20170050951
    Abstract: The present invention relates to triaminopyrimidines and to pharmaceutically acceptable salts thereof, to their use in the treatment and/or prevention of malaria caused by plasmodium species, and to their methods of preparation.
    Type: Application
    Filed: March 26, 2015
    Publication date: February 23, 2017
    Inventors: SHAHUL HAMEED PEER MOHAMED, VIKAS PATIL, KANNAN MURUGAN, EKNATH VITHALRAO BELLALE, ANANDKUMAR RAICHURKAR, SUDHIR LANDGE, JAYASHREE PUTTUR, NILANJANA ROY CHOUDHURY, GAJANAN SHANBHAG, KRISHNA KOUSHIK, PRAVIN IYER, VASAN KIRTHIKA SAMBANDAMURTHY, SURESH SOLAPURE, SHRIDHAR NARAYANAN
  • Publication number: 20160244436
    Abstract: Pharmaceutical compositions described in this document comprise 5-(phenoxymethyl)-1,3-dioxane analogs having a disease-modifying action in the treatment of diseases associated with the production of cortisol that include metabolic syndrome, obesity, headache, depression, hypertension, diabetes mellitus, Cushing's Syndrome, pseudo-Cushing syndrome, cognitive impairment, dementia, heart failure, renal failure, psoriasis, glaucoma, cardiovascular disease, cancer, stroke, incidentalomas, or any diseases involving the overproduction of cortisol.
    Type: Application
    Filed: September 25, 2014
    Publication date: August 25, 2016
    Inventors: Benjamin Eric Blass, Magid A Abou-Gharbia, Wayne E. Childers, Pravin Iyer, Joshodeep Boruwa, Ramreddy Bobbala, Rajashekar Reddy Nimmareddy
  • Publication number: 20160221990
    Abstract: Embodiments of the present invention relate to novel cytochrome P450 inhibitors and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the production of cortisol that include metabolic syndrome, obesity, headache, depression, hypertension, diabetes mellitus, Cushing's Syndrome, pseudo-Cushing syndrome, cognitive impairment, dementia, heart failure, renal failure, psoriasis, glaucoma, cardiovascular disease, cancer, stroke or incidentalomas.
    Type: Application
    Filed: September 15, 2014
    Publication date: August 4, 2016
    Inventors: Benjamin Eric Blass, Magid A Abou-Gharbia, Wayne E. Childers, Pravin Iyer, Joshodeep Boruwa
  • Patent number: 8513425
    Abstract: Compounds of the formula: or pharmaceutically acceptable salts thereof, wherein m, n, Ar, R1, R2, Ra and Rb are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.
    Type: Grant
    Filed: November 21, 2011
    Date of Patent: August 20, 2013
    Assignee: Roche Palo Alto LLC
    Inventors: Pravin Iyer, Clara Jeou Jen Lin, Stephen M. Lynch, Matthew C. Lucas, Ann Marie Madera, Kerem Erol Ozboya, Robert James Weikert, Ryan Craig Schoenfeld
  • Patent number: 8163906
    Abstract: Compounds of formula I are effective modulators of JNK: wherein X is CR11 or N; Y is —C(O)R3, 5-membered heteroaryl, or 5-membered heterocyclyl; Z is phenyl, cycloalkyl, heterocyclyl or heteroaryl, and is substituted with R1 and R2; R1 and R2 are each independently H, halo, CN, lower alkyl, or —Y1—Y2—Y3—R8, or R1 and R2 together form —O(CH2)nO—, where n is 1 or 2; Y1 is —O—, —C(O)—, —C(O)O—, —C(O)NR9—, —NR9C(O)—, —S—, —SO2—, or a bond; Y2 is cycloalkylene, heterocycloalkylene, lower alkylene or a bond; Y3 is —O—, —C(O)—, —C(O)O—, —C(O)NR9—, —NR9C(O)—, —SO2—, or a bond; R8 is H, lower alkyl, lower alkoxy, cycloalkyl, heterocycloalkyl, or —NR9R10, wherein R8 other than H is optionally substituted with lower alkyl, halo, —CF3, or —OH; R9 and R10 are each independently H or lower alkyl; R3 is OH, lower alkyl, lower alkoxy, (lower alkoxy)-lower alkoxy, or —NR9R10; R4 is lower alkyl, phenyl, heterocyclyl, cycloalkyl, heterocycloalkyl, or heteroaryl, and is optionally substituted with lower alkyl, hydro
    Type: Grant
    Filed: May 14, 2008
    Date of Patent: April 24, 2012
    Assignee: Roche Palo Alto, LLC
    Inventors: Sarah C. Abbot, Geneviève N. Boice, Bernd Buettelmann, David Michael Goldstein, Leyi Gong, Joan Heather Hogg, Pravin Iyer, Kristen Lynn McCaleb, Yun-chou Tan
  • Publication number: 20120065225
    Abstract: Compounds of the formula: or pharmaceutically acceptable salts thereof, wherein m, n, Ar, R1, R2, Ra and Rb are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.
    Type: Application
    Filed: November 21, 2011
    Publication date: March 15, 2012
    Inventors: Pravin Iyer, Clara Jeou Jen Lin, Stephen M. Lynch, Matthew C. Lucas, Ann Marie Madera, Kerem Erol Ozboya, Robert James Weikert, Ryan Craig Schoenfeld
  • Patent number: 8093285
    Abstract: This application discloses aminopiperidinyl compounds of generic Formulae I-II: or pharmaceutically acceptable salts thereof, wherein m, r, Q1, Q2, Q3, R, Ra, R1, R2a, R2b, and R3 are defined as described herein, useful for treatment of diseases associated with monoamine reuptake inhibitors. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.
    Type: Grant
    Filed: March 25, 2009
    Date of Patent: January 10, 2012
    Assignee: Roche Palo Alto LLC
    Inventors: Pravin Iyer, Matthew C. Lucas, Ryan Craig Schoenfeld, Robert James Weikert
  • Patent number: 8084623
    Abstract: Compounds of the formula: or pharmaceutically acceptable salts thereof, wherein m, n, Ar, R1, R2, Ra and Rb are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.
    Type: Grant
    Filed: December 18, 2007
    Date of Patent: December 27, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Pravin Iyer, Clara Jeou Jen Lin, Stephen M. Lynch, Matthew C. Lucas, Ann Marie Madera, Kerem Erol Ozboya, Robert James Weikert, Ryan Craig Schoenfeld
  • Patent number: 7803830
    Abstract: The present invention provides compounds of the formula: or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein p, Ar, R1, R2, R3, Ra, Rb, Rc, Rd and Re are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.
    Type: Grant
    Filed: October 8, 2008
    Date of Patent: September 28, 2010
    Assignee: Roche Palo Alto LLC
    Inventors: Pravin Iyer, Matthew C. Lucas, Ryan Craig Schoenfeld, Marzia Villa, Robert James Weikert
  • Publication number: 20090318493
    Abstract: Aryl and heteroaryl ketone compounds substituted with pyrrolidines and piperidines, that modulate serotonin norepinephrine and/or dopamine neurotransmission. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.
    Type: Application
    Filed: June 17, 2009
    Publication date: December 24, 2009
    Inventors: Pravin Iyer, Clara Jeou Jen Lin, Matthew C. Lucas, Stephen M. Lynch, Ann Marie Madera, Kerem Erol Ozboya, Ryan Craig Schoenfeld, Robert James Weikert